Kestra Medical Technologies (NASDAQ:KMTS) Insider Traci Umberger Sells 3,580 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 3,580 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.04, for a total transaction of $86,063.20. Following the sale, the insider directly owned 195,825 shares in the company, valued at approximately $4,707,633. This trade represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Trading Up 0.8%

Shares of KMTS traded up $0.21 during midday trading on Thursday, hitting $25.27. 184,867 shares of the company traded hands, compared to its average volume of 393,651. Kestra Medical Technologies, Ltd. has a one year low of $14.10 and a one year high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The stock has a 50-day moving average of $22.86 and a 200-day moving average of $22.54.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million for the quarter. As a group, research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on KMTS shares. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Oppenheimer began coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They issued a “market perform” rating for the company. The Goldman Sachs Group reduced their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $27.83.

Hedge Funds Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC bought a new stake in Kestra Medical Technologies in the fourth quarter valued at approximately $31,000. Russell Investments Group Ltd. raised its holdings in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. purchased a new stake in Kestra Medical Technologies during the 4th quarter valued at $72,000. Finally, Brown Brothers Harriman & Co. grew its holdings in Kestra Medical Technologies by 26.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.